| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
43,254 |
31,860 |
$1.76M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
23,375 |
17,016 |
$677K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
14,277 |
10,065 |
$196K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,995 |
2,149 |
$114K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
631 |
457 |
$100K |
| 94010 |
|
4,449 |
3,332 |
$70K |
| 80305 |
|
11,518 |
9,028 |
$63K |
| 81025 |
|
14,504 |
11,095 |
$61K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
784 |
612 |
$48K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
1,013 |
819 |
$47K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,380 |
1,158 |
$40K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
450 |
399 |
$39K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
654 |
546 |
$38K |
| 81002 |
|
24,678 |
17,494 |
$36K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,355 |
2,176 |
$36K |
| 93000 |
|
3,398 |
2,624 |
$34K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
287 |
223 |
$30K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,897 |
3,164 |
$30K |
| 36415 |
Collection of venous blood by venipuncture |
17,603 |
14,169 |
$22K |
| 81003 |
|
20,868 |
16,108 |
$21K |
| 99406 |
|
2,907 |
2,108 |
$16K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,205 |
871 |
$13K |
| 99497 |
|
596 |
416 |
$10K |
| 93922 |
|
429 |
345 |
$10K |
| 82947 |
|
5,195 |
3,658 |
$10K |
| E0570 |
Nebulizer, with compressor |
582 |
389 |
$7K |
| 1159F |
|
26,642 |
19,123 |
$6K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
159 |
137 |
$6K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,559 |
2,651 |
$6K |
| 1160F |
|
26,517 |
19,139 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
168 |
127 |
$4K |
| 93225 |
|
206 |
161 |
$4K |
| 96127 |
|
1,211 |
868 |
$4K |
| 69210 |
|
146 |
90 |
$4K |
| 3074F |
|
19,559 |
14,798 |
$3K |
| 36416 |
|
4,236 |
3,043 |
$3K |
| 96160 |
|
1,266 |
861 |
$3K |
| 3078F |
|
16,147 |
12,297 |
$3K |
| 3079F |
|
8,760 |
6,883 |
$3K |
| 3008F |
|
26,800 |
19,502 |
$2K |
| 1125F |
|
2,496 |
1,836 |
$2K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,607 |
939 |
$2K |
| 93925 |
|
31 |
28 |
$2K |
| 86308 |
|
683 |
521 |
$2K |
| 93227 |
|
127 |
116 |
$2K |
| 3077F |
|
3,107 |
2,371 |
$2K |
| 99441 |
|
128 |
114 |
$2K |
| 99350 |
Prolong home eval add 15m |
105 |
61 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,956 |
3,802 |
$2K |
| 1126F |
|
1,551 |
1,221 |
$2K |
| 95117 |
|
231 |
94 |
$2K |
| 93975 |
|
23 |
14 |
$2K |
| 76770 |
|
62 |
49 |
$2K |
| 82962 |
|
1,371 |
886 |
$1K |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
305 |
224 |
$1K |
| 1170F |
|
3,116 |
2,437 |
$1K |
| A7005 |
Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable |
251 |
150 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
61 |
52 |
$1K |
| 3075F |
|
3,477 |
2,771 |
$1K |
| 3080F |
|
1,829 |
1,422 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
172 |
97 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,356 |
1,032 |
$1K |
| 93978 |
|
12 |
12 |
$973.84 |
| 93970 |
|
15 |
15 |
$936.37 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
46 |
37 |
$821.49 |
| 93880 |
|
13 |
13 |
$735.37 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
158 |
104 |
$684.73 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
19 |
17 |
$658.16 |
| 94664 |
|
81 |
44 |
$532.21 |
| 96161 |
|
139 |
75 |
$354.86 |
| 99051 |
|
279 |
233 |
$322.06 |
| 99349 |
|
82 |
24 |
$162.24 |
| 92551 |
|
22 |
12 |
$119.55 |
| 99386 |
|
148 |
64 |
$116.46 |
| G0245 |
Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) which must include: (1) the diagnosis of lops, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear and (4) patient education |
19 |
19 |
$47.70 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
111 |
63 |
$24.74 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
131 |
74 |
$7.75 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
30 |
21 |
$0.15 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
121 |
94 |
$0.00 |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
185 |
139 |
$0.00 |
| 99387 |
|
117 |
52 |
$0.00 |
| 99366 |
|
935 |
422 |
$0.00 |
| 3044F |
|
176 |
145 |
$0.00 |